Core Points - The company has recognized Mr. Zhao Liwen as a core technical personnel, enhancing its innovation capabilities and technical level [1] - Mr. Zhao possesses comprehensive experience in the entire process of innovative drug development, including early discovery, IND application, and clinical development [1] - He has led the development of various innovative drug forms, including small molecules, antibody-drug conjugates (ADC), and protein degradation-targeted chimeras (PROTAC), advancing over 10 drugs into clinical stages [1] - Two first-class innovative drugs designed and invented by him have been approved for market by the National Medical Products Administration [1] - This personnel change is expected to accelerate the implementation of the company's innovation transformation strategy [1]